Taipei Exchange - Delayed Quote TWD

Original BioMedicals Co., Ltd. (6483.TWO)

12.05
+0.05
+(0.42%)
At close: 2:10:09 PM GMT+8
Loading Chart for 6483.TWO
  • Previous Close 12.00
  • Open 12.05
  • Bid 11.60 x --
  • Ask 12.00 x --
  • Day's Range 11.65 - 12.05
  • 52 Week Range 9.93 - 21.00
  • Volume 28,885
  • Avg. Volume 228,901
  • Market Cap (intraday) 795.204M
  • Beta (5Y Monthly) 0.08
  • PE Ratio (TTM) --
  • EPS (TTM) -1.14
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Original BioMedicals Co., Ltd., a biotechnology company, chemical entities to solve unmet medical needs in Taiwan. It develops (A01) Radprotect, a pre-clinical product to protects against radiation exposer; (A02) CCM-Ami, which protects normal tissues from the toxic effects of chemotherapeutic agents and ionizing radiation; and ((P01)GLP-1 CCM for the treatment of type 2 diabetes. The company was founded in 2011 and is based in Taipei, Taiwan.

www.i-obm.com/English_Version/index.aspx

23

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 6483.TWO

View More

Performance Overview: 6483.TWO

Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

6483.TWO
4.78%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
5.66%

1-Year Return

6483.TWO
25.16%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
2.76%

3-Year Return

6483.TWO
29.94%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
37.25%

5-Year Return

6483.TWO
29.94%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
100.93%

Compare To: 6483.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 6483.TWO

View More

Valuation Measures

Annual
As of 5/14/2025
  • Market Cap

    791.90M

  • Enterprise Value

    562.70M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    3.10

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -15.06%

  • Return on Equity (ttm)

    -25.78%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -75M

  • Diluted EPS (ttm)

    -1.14

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    241.19M

  • Total Debt/Equity (mrq)

    4.70%

  • Levered Free Cash Flow (ttm)

    -60.06M

Research Analysis: 6483.TWO

View More

Company Insights: 6483.TWO

Research Reports: 6483.TWO

View More